Viking Therapeutics develops novel therapies for metabolic and endocrine disorders with a primary focus on VK2809. This drug candidate is a thyroid hormone receptor beta agonist that treats patients with non-alcoholic steatohepatitis and NAFLD. The company also develops VK5211, VK0612, and VK0214 orally available drugs for various treatments.